Wellington Management Group LLP Sells 97,475 Shares of Omnicell, Inc. (NASDAQ:OMCL)

Wellington Management Group LLP cut its position in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 23.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 325,564 shares of the company's stock after selling 97,475 shares during the quarter. Wellington Management Group LLP owned approximately 0.70% of Omnicell worth $14,494,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of OMCL. Vanguard Group Inc. grew its stake in shares of Omnicell by 0.5% during the 4th quarter. Vanguard Group Inc. now owns 5,562,165 shares of the company's stock valued at $247,628,000 after buying an additional 28,573 shares during the period. Victory Capital Management Inc. grew its stake in Omnicell by 32.9% in the fourth quarter. Victory Capital Management Inc. now owns 1,526,309 shares of the company's stock worth $67,951,000 after purchasing an additional 377,883 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. increased its holdings in shares of Omnicell by 93.3% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,450,416 shares of the company's stock valued at $64,573,000 after acquiring an additional 699,925 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Omnicell by 0.3% during the third quarter. Geode Capital Management LLC now owns 1,104,745 shares of the company's stock worth $48,176,000 after purchasing an additional 2,877 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its stake in Omnicell by 3.6% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 616,153 shares of the company's stock worth $27,431,000 after acquiring an additional 21,157 shares during the period. 97.70% of the stock is owned by hedge funds and other institutional investors.

Omnicell Stock Up 0.7 %

OMCL traded up $0.22 on Monday, reaching $31.41. 11,486 shares of the company traded hands, compared to its average volume of 513,324. The stock's 50 day moving average price is $36.34 and its 200-day moving average price is $41.67. The company has a market cap of $1.47 billion, a price-to-earnings ratio of 116.63, a PEG ratio of 7.53 and a beta of 0.78. Omnicell, Inc. has a 52-week low of $25.12 and a 52-week high of $55.74. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.37 and a quick ratio of 1.22.

Omnicell (NASDAQ:OMCL - Get Free Report) last issued its earnings results on Thursday, February 6th. The company reported $0.45 EPS for the quarter, missing analysts' consensus estimates of $0.57 by ($0.12). Omnicell had a net margin of 1.13% and a return on equity of 3.82%. On average, sell-side analysts expect that Omnicell, Inc. will post 1.09 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the company. StockNews.com lowered Omnicell from a "buy" rating to a "hold" rating in a research report on Monday, March 24th. Bank of America decreased their target price on Omnicell from $54.00 to $46.00 and set a "neutral" rating for the company in a research note on Monday, January 6th. Benchmark reaffirmed a "buy" rating and issued a $62.00 price target on shares of Omnicell in a report on Tuesday, February 4th. JPMorgan Chase & Co. cut their target price on Omnicell from $44.00 to $36.00 and set a "neutral" rating on the stock in a research report on Thursday, March 20th. Finally, Wells Fargo & Company cut their price objective on Omnicell from $49.00 to $40.00 and set an "equal weight" rating on the stock in a report on Monday, January 13th. Five investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $51.00.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.